15:21 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Ionis' Akcea reports Phase I/IIa data for AKCEA-APOCIII-LRx in hypertriglyceridemia

In October, Akcea Therapeutics Inc. (NASDAQ:AKCA) reported data from a Phase I/IIa trial in about 56 healthy volunteers and patients with hypertriglyceridemia showing that AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) led to reductions in apolipoprotein C-III (APOCIII; APOC3) protein...
19:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100 patients with hypertriglyceridemia and established cardiovascular disease (CVD). AKCEA-APOCIII-LRx is a ligand conjugated antisense version...
21:06 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

AKCEA-APO(a)-LRx: Ph IIb started

Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease. In January, Ionis and...
18:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea...
23:50 , Mar 27, 2017 |  BC Extra  |  Financial News

Ionis lipid spinout Akcea targets $100M IPO

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million, according to a regulatory filing. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN)...
19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

Ionis, Novartis deal

Ionis and its Akcea Therapeutics Inc. subsidiary granted Novartis exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are antisense therapies for cardiovascular disorders. Ionis and Akcea will receive an upfront...
23:51 , Jan 6, 2017 |  BC Extra  |  Company News

Ionis, Novartis forge cardiovascular deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and its Akcea Therapeutics subsidiary granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are antisense therapies for cardiovascular disorders. Ionis and Akcea...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...